Zhejiang Jiuzhou Pharmaceutical Co., Ltd

SHSE:603456 Stock Report

Market Cap: CN¥12.3b

Zhejiang Jiuzhou Pharmaceutical Future Growth

Future criteria checks 2/6

Zhejiang Jiuzhou Pharmaceutical is forecast to grow earnings and revenue by 16.4% and 14.7% per annum respectively. EPS is expected to grow by 16.4% per annum. Return on equity is forecast to be 14.9% in 3 years.

Key information

16.4%

Earnings growth rate

16.4%

EPS growth rate

Pharmaceuticals earnings growth18.4%
Revenue growth rate14.7%
Future return on equity14.9%
Analyst coverage

Good

Last updated20 May 2024

Recent future growth updates

Zhejiang Jiuzhou Pharmaceutical Co., Ltd Just Missed Revenue By 17%: Here's What Analysts Think Will Happen Next

Apr 11
Zhejiang Jiuzhou Pharmaceutical Co., Ltd Just Missed Revenue By 17%: Here's What Analysts Think Will Happen Next

Recent updates

Here's Why Zhejiang Jiuzhou Pharmaceutical (SHSE:603456) Can Manage Its Debt Responsibly

Jun 13
Here's Why Zhejiang Jiuzhou Pharmaceutical (SHSE:603456) Can Manage Its Debt Responsibly

Zhejiang Jiuzhou Pharmaceutical Co., Ltd's (SHSE:603456) Business And Shares Still Trailing The Market

May 24
Zhejiang Jiuzhou Pharmaceutical Co., Ltd's (SHSE:603456) Business And Shares Still Trailing The Market

Zhejiang Jiuzhou Pharmaceutical's (SHSE:603456) Solid Earnings May Rest On Weak Foundations

May 01
Zhejiang Jiuzhou Pharmaceutical's (SHSE:603456) Solid Earnings May Rest On Weak Foundations

Zhejiang Jiuzhou Pharmaceutical Co., Ltd Just Missed Revenue By 17%: Here's What Analysts Think Will Happen Next

Apr 11
Zhejiang Jiuzhou Pharmaceutical Co., Ltd Just Missed Revenue By 17%: Here's What Analysts Think Will Happen Next

Zhejiang Jiuzhou Pharmaceutical Co., Ltd (SHSE:603456) Shares Could Be 32% Above Their Intrinsic Value Estimate

Feb 28
Zhejiang Jiuzhou Pharmaceutical Co., Ltd (SHSE:603456) Shares Could Be 32% Above Their Intrinsic Value Estimate

Earnings and Revenue Growth Forecasts

SHSE:603456 - Analysts future estimates and past financials data (CNY Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20267,9541,556N/A2,0104
12/31/20257,2511,513N/A1,7475
12/31/20246,2941,259N/A1,5745
3/31/20245,248989-185767N/A
12/31/20235,5231,0334311,360N/A
9/30/20235,6491,1453111,135N/A
6/30/20235,7451,0755241,386N/A
3/31/20235,8239945181,300N/A
12/31/20225,4459215121,226N/A
9/30/20225,4329047871,490N/A
6/30/20225,1508274501,098N/A
3/31/20224,5817474481,050N/A
12/31/20214,06363498678N/A
9/30/20213,906614-71456N/A
6/30/20213,507526115494N/A
3/31/20213,112443-59330N/A
12/31/20202,64738185400N/A
9/30/20202,404341308612N/A
6/30/20202,16726511357N/A
3/31/20202,010227206529N/A
12/31/20192,017238234554N/A
9/30/20191,95219843357N/A
6/30/20191,800171127406N/A
3/31/20191,785149114363N/A
12/31/20181,86215734265N/A
9/30/20181,752128186325N/A
6/30/20181,839163171282N/A
3/31/20181,79815798215N/A
12/31/20171,717148N/A275N/A
9/30/20171,696139N/A157N/A
6/30/20171,694147N/A177N/A
3/31/20171,697116N/A85N/A
12/31/20161,653111N/A137N/A
9/30/20161,559118N/A83N/A
6/30/20161,500126N/A44N/A
3/31/20161,458197N/A73N/A
12/31/20151,445200N/A141N/A
9/30/20151,432195N/A110N/A
6/30/20151,349170N/A98N/A
3/31/20151,325142N/A184N/A
12/31/20141,286133N/A10N/A
9/30/20141,229155N/A138N/A
12/31/20131,310166N/A204N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 603456's forecast earnings growth (16.4% per year) is above the savings rate (2.9%).

Earnings vs Market: 603456's earnings (16.4% per year) are forecast to grow slower than the CN market (22.2% per year).

High Growth Earnings: 603456's earnings are forecast to grow, but not significantly.

Revenue vs Market: 603456's revenue (14.7% per year) is forecast to grow faster than the CN market (13.7% per year).

High Growth Revenue: 603456's revenue (14.7% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: 603456's Return on Equity is forecast to be low in 3 years time (14.9%).


Discover growth companies

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.